Table 1.
Characteristics of the patients at baseline
| Characteristic | Cohort N = 31 |
|---|---|
| Age (years) | 63 ± 13 |
| Female sex, n (%) | 6 (19) |
| Black race, n (%) a | 4 (13) |
| Weight (kg) | 90 ± 23 |
| Systolic blood pressure (mmHg) | 113 ± 21 |
| Diastolic blood pressure (mmHg) | 64 ± 10 |
| Mean arterial pressure (mmHg) | 83 ± 15 |
| Heart rate (beats/min) | 80 ± 16 |
| SpO2 (%) | 96 ± 2 |
| Serum creatinine (mg/dL) | 1.7 ± 1.0 |
| BUN (mg/dL) | 48 ± 28 |
| Blood glucose (mg/dL) | 151 ± 61 |
| Haemoglobin (mg/dL) | 10.5 ± 2.7 |
| Haematocrit (%) | 33 ± 7 |
| Left ventricular ejection fraction (%) | 40 ± 20 |
| HFrEF, n (%) | 17 (55) |
| Haemoglobin A1C ≥ 6.5 | 18 (58) |
| Haemoglobin A1C | 7.0 ± 1.5 |
| Estimated GFR by CKD‐EPI | |
| Mean (mL/min/1.73 m2) | 50.2 ± 24.0 |
| Rate of <60 mL/min/1.73 m2, n (%) | 19 (61) |
| In‐hospital therapy b | |
| LVAD, n (%) | 9 (29) |
| Vasopressor and/or inotrope, n (%) | 10 (32) |
| Loop diuretic dose (furosemide equivalents) | 160 (30–320) |
| Loop diuretic administered | |
| Furosemide | 16 (52) |
| Bumetanide | 15 (48) |
| Thiazides, n (%) | 8 (26) |
| Thiazide dose (mg of metolazone equivalents) | 13 |
BUN, blood urea nitrogen; CKD‐EPI, Chronic Kidney Disease Epidemiology Collaboration; GFR, glomerular filtration rate; HFrEF, heart failure with reduced ejection fraction; LVAD, left ventricular assist device; SpO2, peripheral capillary oxygen saturation.Body mass index was calculated as weight in kilograms divided by the square of the height in metres.
a
Race was identified through review of the electronic health record.
b
Therapy received during the day of SGLT‐2i initiation.